The FDA issued a warning letter to a Chinese supplier, Harbin Jixianglong Biotech, after inspectors found alleged compliance failures involving semaglutide API shipments amid the agency’s “green list” import restrictions. FDA said the company purchased semaglutide from a facility not on the green list and allegedly relabeled the APIs as manufactured at a permitted plant. The agency expressed concern that the relabeling could circumvent safeguards designed to reduce patient risk from unverified sources and substandard inputs. FDA also cited issues with batch records and documentation around repackaging and labeling. For the GLP-1 supply chain, the letter highlights enforcement momentum tied to API traceability and manufacturing provenance as demand for these drugs continues to stress global sourcing networks.